{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T11:31:10Z","timestamp":1764588670421,"version":"build-2065373602"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"DOI":"10.7759\/cureus.94784","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:58:53Z","timestamp":1760702333000},"source":"Crossref","is-referenced-by-count":1,"title":["Successful Sequential Use of the Antibody-Drug Conjugate Trastuzumab Deruxtecan After Progression on Sacituzumab Govitecan in a Recurrent Treatment-Resistant Ovarian Cancer Patient: A Case Report"],"prefix":"10.7759","author":[{"given":"Victoria M","family":"Ettorre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Greenman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cem","family":"Demirkiran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro D","family":"Santin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres LC","year":"2019","unstructured":"Peres LC, Cushing-Haugen KL, K\u00f6bel M, et al.. Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst. 2019, 111:60-8. 10.1093\/jnci\/djy071","journal-title":"J Natl Cancer Inst"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul P","year":"2020","unstructured":"Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody-drug conjugates: a comprehensive review. Mol Cancer Res. 2020, 18:3-19. 10.1158\/1541-7786.MCR-19-0582","journal-title":"Mol Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000522206","article-title":"Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors","volume":"89","author":"Dum D","year":"2022","unstructured":"Dum D, Taherpour N, Menz A, et al.. Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors. Pathobiology. 2022, 89:245-58. 10.1159\/000522206","journal-title":"Pathobiology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00118","article-title":"Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan (SN-38), in ovarian cancer","volume":"10","author":"Perrone E","year":"2020","unstructured":"Perrone E, Lopez S, Zeybek B, et al.. Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan (SN-38), in ovarian cancer. Front Oncol. 2020, 10:118. 10.3389\/fonc.2020.00118","journal-title":"Front Oncol"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.776","article-title":"714MO Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): results from the phase II TROPION-PanTumor03 study","volume":"35","author":"Oaknin A","year":"2024","unstructured":"Oaknin A, Ang JE, Rha SY, et al.. 714MO Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): results from the phase II TROPION-PanTumor03 study. Ann Oncol. 2024, 35:547-8.","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2024.101459","article-title":"Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer","volume":"54","author":"Greenman M","year":"2024","unstructured":"Greenman M, Bellone S, Demirkiran C, Max Philipp Hartwich T, Santin AD. Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer. Gynecol Oncol Rep. 2024, 54:101459. 10.1016\/j.gore.2024.101459","journal-title":"Gynecol Oncol Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam F","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, et al.. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024, 42:47-58. 10.1200\/JCO.23.02005","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2025.2535178","article-title":"Clinical pharmacologic considerations for antibody-drug conjugate in gynecologic cancers","volume":"18","author":"Ettorre VM","year":"2025","unstructured":"Ettorre VM, Palmieri L, Santin AD. Clinical pharmacologic considerations for antibody-drug conjugate in gynecologic cancers. Expert Rev Clin Pharmacol. 2025, 18:461-9. 10.1080\/17512433.2025.2535178","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu Z","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy. Signal Transduct Target Ther. 2022, 7:93. 10.1038\/s41392-022-00947-7","journal-title":"Signal Transduct Target Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00748-5","article-title":"Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)","volume":"11","author":"Huppert LA","year":"2025","unstructured":"Huppert LA, Mahtani R, Fisch S, et al.. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC). NPJ Breast Cancer. 2025, 11:34. 10.1038\/s41523-025-00748-5","journal-title":"NPJ Breast Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02766-9","article-title":"Efficacy of administration sequence: sacituzumab govitecan and trastuzumab deruxtecan in HER2-low metastatic breast cancer","volume":"131","author":"Poumeaud F","year":"2024","unstructured":"Poumeaud F, Morisseau M, Cabel L, et al.. Efficacy of administration sequence: sacituzumab govitecan and trastuzumab deruxtecan in HER2-low metastatic breast cancer. Br J Cancer. 2024, 131:702-8. 10.1038\/s41416-024-02766-9","journal-title":"Br J Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.274","article-title":"T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo","volume":"3","author":"English DP","year":"2014","unstructured":"English DP, Bellone S, Schwab CL, et al.. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. Cancer Med. 2014, 3:1256-65. 10.1002\/cam4.274","journal-title":"Cancer Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-024-10297-z","article-title":"Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2","volume":"41","author":"Mutlu L","year":"2024","unstructured":"Mutlu L, McNamara B, Bellone S, et al.. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clin Exp Metastasis. 2024, 41:765-75. 10.1007\/s10585-024-10297-z","journal-title":"Clin Exp Metastasis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2020.08.006","article-title":"Trastuzumab deruxtecan (DS-8201a): the latest research and advances in breast cancer","volume":"21","author":"Andrikopoulou A","year":"2021","unstructured":"Andrikopoulou A, Zografos E, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F. Trastuzumab deruxtecan (DS-8201a): the latest research and advances in breast cancer. Clin Breast Cancer. 2021, 21:e212-9. 10.1016\/j.clbc.2020.08.006","journal-title":"Clin Breast Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.1022","article-title":"Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study","volume":"41","author":"Abelman RO","year":"2023","unstructured":"Abelman RO, Spring L, Fell GG, et al.. Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study. J Clin Oncol. 2023, 41:1022. 10.1200\/JCO.2023.41.16_suppl.1022","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/422047-successful-sequential-use-of-the-antibody-drug-conjugate-trastuzumab-deruxtecan-after-progression-on-sacituzumab-govitecan-in-a-recurrent-treatment-resistant-ovarian-cancer-patient-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:58:55Z","timestamp":1760702335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/422047-successful-sequential-use-of-the-antibody-drug-conjugate-trastuzumab-deruxtecan-after-progression-on-sacituzumab-govitecan-in-a-recurrent-treatment-resistant-ovarian-cancer-patient-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.94784","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}